Perzea Launch by Hetero Healthcare and Enzene Supports India’s Vision of Accessible Cancer Care

Hyderabad (Telangana) [India], September 25: Reinforcing the Government of India’s mission to provide equitable healthcare, Hetero Healthcare Limited, in partnership with Enzene Biosciences, has launched Perzea, its most affordable biosimilar Pertuzumab for HER2-positive breast cancer. This initiative underlines the critical need for advanced cancer treatment accessibility in the country.

Closing the Treatment Gap
Pertuzumab, a globally accepted monoclonal antibody therapy, significantly improves outcomes when used with trastuzumab…